Axonics® announces pricing of public offering of common stock

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) (“axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it priced its previously announced underwritten public offering of 1,750,000 shares of its common stock. the offering is expected to close on august 5, 2022, subject to the satisfaction of customary closing conditions. axonics has granted the underwriter a 30-d
AXNX Ratings Summary
AXNX Quant Ranking